3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
3
Unknown
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Gastrointestinal
1
Dermatologic
1
Conditions
Pathologic Complete Response
1
Leukemia, Myeloid, Acute
1
Interventions
venetoclax
75
Cyclophosphamide
68
Cytarabine
59
fludarabine
49
Azacitidine
44
Specimen Handling
36
fludarabine phosphate
35
Rituximab
34
Biopsy
30
Methotrexate
28
ibrutinib
27
Daunorubicin
25
Dexamethasone
24
Vincristine
23
obinutuzumab
21
Etoposide
21
Decitabine
21
acalabrutinib
19
Tacrolimus
19
Dasatinib
19
blinatumomab
18
Melphalan
18
Prednisone
16
Mycophenolic Acid
16
Granulocyte Colony-Stimulating Factor
16
Busulfan
16
Whole-Body Irradiation
15
Doxorubicin
15
Injections
14
pegaspargase
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Monatide (IMS 3015)
×
Other hematologic neoplasm
×
Clear all
NCT04229979
2025-10-01
REGAL
Sellas Life Sciences Group
Phase 3
Active not recruiting
127 enrolled